Skip to main content

5 Result(s)

within J. Fagerberg Remove this filter

and

  1. No Access

    Article

    Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

    Granulocyte/macrophage-colony-stimulating factor (GM-CSF) has previously been indicated to enhance the therapeutic effect of the anti-colorectal carcinoma mAb17-1A as well as to augment in vivo immune effecto...

    A.-L. Hjelm Skog, P. Ragnhammar, J. Fagerberg… in Cancer Immunology, Immunotherapy (1999)

  2. No Access

    Article

    Ear tumours induced by experimental carcinogenesis in the rat: excision prevents early death

    1,2-dimethylhydrazine (DMH) is widely used to induce colorectal tumours in rodents. Some of the animals develop ear as well as colorectal tumours. Rats with large, ulcerated ear tumours are usually sacrificed ...

    J. Shetye, T. Mathiesen, J. Fagerberg… in International Journal of Colorectal Disease (1994)

  3. No Access

    Article

    Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

    The antitumor effector functions of unconjugated monoclonal antibodies (mAb) in cancer therapy are not fully understood. Direct cytotoxic mechanisms such as antibody-dependent cellular cytotoxicity, complement...

    J. Fagerberg, J. -E. Frödin, P. Ragnhammar, M. Steinitz… in Cancer Immunology, Immunotherapy (1994)

  4. No Access

    Article

    Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma

    Pretreatment with a low dose of cyclophosphamide (CY) has been claimed to inhibit suppressor functions and augment various immune functions. A combination of a low dose of CY, α-interferon (IFN-α) and continuo...

    J.P WersÄll, G. Masucci, A-L Hjelm… in Medical Oncology and Tumor Pharmacotherapy (1993)

  5. No Access

    Article

    Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

    The antitumor effector functions of unconjugated monoclonal antibodies in cancer therapy are complex. Direct cytotoxic mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytolysi...

    J. Fagerberg, J-E. Frödin, H. Wigzell, H. Mellstedt in Cancer Immunology, Immunotherapy (1993)